This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2019 Sep 3;322(9):821-823.

doi: 10.1001/jama.2019.9689.

Medications to Reduce Breast Cancer Risk: Promise and Limitations

Lydia E Pace^{1

2}, Nancy L Keating^{2

3}

Affiliations

Affiliations

¹ Division of Women's Health, Brigham and Women's Hospital, Boston, Massachusetts.
² Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

PMID: 31479121
DOI: 10.1001/jama.2019.9689

Editorial

Medications to Reduce Breast Cancer Risk: Promise and Limitations

Lydia E Pace et al. JAMA. 2019.

. 2019 Sep 3;322(9):821-823.

doi: 10.1001/jama.2019.9689.

Authors

Lydia E Pace^{1

2}, Nancy L Keating^{2

3}

Affiliations

¹ Division of Women's Health, Brigham and Women's Hospital, Boston, Massachusetts.
² Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

PMID: 31479121
DOI: 10.1001/jama.2019.9689

No abstract available

PubMed Disclaimer

Comment on

Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. Nelson HD, et al. JAMA. 2019 Sep 3;322(9):868-886. doi: 10.1001/jama.2019.5780. JAMA. 2019. PMID: 31479143
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB. US Preventive Services Task Force, et al. JAMA. 2019 Sep 3;322(9):857-867. doi: 10.1001/jama.2019.11885. JAMA. 2019. PMID: 31479144

Similar articles

Effects of counseling Ashkenazi Jewish women about breast cancer risk.
Bowen DJ, Burke W, Culver JO, Press N, Crystal S. Bowen DJ, et al. Cultur Divers Ethnic Minor Psychol. 2006 Jan;12(1):45-56. doi: 10.1037/1099-9809.12.1.45. Cultur Divers Ethnic Minor Psychol. 2006. PMID: 16594854 Clinical Trial.
Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. Nelson HD, et al. Ann Intern Med. 2009 Nov 17;151(10):703-15, W-226-35. doi: 10.7326/0003-4819-151-10-200911170-00147. Ann Intern Med. 2009. PMID: 19920271 Review.
Opportunities and strategies for breast cancer prevention through risk reduction.
Mahoney MC, Bevers T, Linos E, Willett WC. Mahoney MC, et al. CA Cancer J Clin. 2008 Nov-Dec;58(6):347-71. doi: 10.3322/CA.2008.0016. Epub 2008 Nov 3. CA Cancer J Clin. 2008. PMID: 18981297 Review.
Prevention of breast cancer (Part II): risk reduction strategies.
Tirona MT, Sehgal R, Ballester O. Tirona MT, et al. Cancer Invest. 2010 Dec;28(10):1070-7. doi: 10.3109/07357907.2010.512593. Epub 2010 Oct 11. Cancer Invest. 2010. PMID: 20932221 Review.
Lifestyle changes to reduce the risk of breast cancer.
Hairon N. Hairon N. Nurs Times. 2007 Oct 9-15;103(41):23-4. Nurs Times. 2007. PMID: 17985726 No abstract available.

See all similar articles

Cited by

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
Kotsopoulos J, Gronwald J, Huzarski T, Aeilts A, Randall Armel S, Karlan B, Singer CF, Eisen A, Tung N, Olopade O, Bordeleau L, Eng C, Foulkes WD, Neuhausen SL, Cullinane CA, Pal T, Fruscio R, Lubinski J, Metcalfe K, Sun P, Narod SA; and the Hereditary Breast Cancer Clinical Study Group. Kotsopoulos J, et al. Breast Cancer Res Treat. 2023 Sep;201(2):257-264. doi: 10.1007/s10549-023-06991-3. Epub 2023 Jul 11. Breast Cancer Res Treat. 2023. PMID: 37432545
Factors to Consider in Developing Breast Cancer Risk Models to Implement into Clinical Care.
Buist DSM. Buist DSM. Curr Epidemiol Rep. 2020 Jun;7(2):113-116. doi: 10.1007/s40471-020-00230-9. Epub 2020 Apr 29. Curr Epidemiol Rep. 2020. PMID: 33552842 Free PMC article.
Breast cancer screening programs: does one risk fit all?
Pediconi F, Galati F. Pediconi F, et al. Quant Imaging Med Surg. 2020 Apr;10(4):886-890. doi: 10.21037/qims.2020.03.14. Quant Imaging Med Surg. 2020. PMID: 32355656 Free PMC article. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information